参考文献 Anna Wagner, Heike Grabsch, Murielle Mauer, et al. EORTC-1203 GITC "INNOVATION": Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy of HER-2 positive stomach c
Gastric (stomach) cancer is the fifth most common cancer worldwide and the third leading cause of cancer mortality with a five-year survival rate of 5% for metastatic disease; there were approximately one million new cases reported in 2018 and 783,000 deaths.Incidence rates for gastric cancer a...
About HER2 Positive Gastric CancerGastric (stomach) cancer is the fifth most common cancer worldwide and the fifth leading cause of cancer-related death.1,2 Approximately one million cases of gastric cancer were diagnosed in 2022.2 Gastric cancer is associated with a poor prognosis, particu...
About HER2 Positive Gastric Cancer Gastric (stomach) cancer is the fifth most common cancer worldwide and the fourth highest leading cause of cancer mortality, with a five-year global survival rate of 5% to 10% for advanced or metastatic disease.1,2,3Approximately one million new patients were...
Gastric (stomach) cancer is the fifth most common cancer worldwide and the third leading cause of cancer mortality with a five-year survival rate of 5% for metastatic disease; there were approximately one million new cases reported in 2018 and 783,000 deaths.3,4In...
A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer Article Open access 12 October 2022 Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in ...
Genetic amplification of HER2 drives tumorigenesis and cancer progression in a subset of patients with gastric cancer (GC), and treatment with trastuzumab, a humanized HER2-neutralizing antibody, improves the overall survival rate of HER2-positive patients. However, a considerable portion of the patient...
and also takes part in organogenesis and development14. Overexpression of Her2 or gene amplification occurs in 20–30% of cases of breast cancer and correlates with a poor prognosis of survival in patients. Anti-Her2 therapy is currently approved for Her2 overexpression in breast, stomach, and ga...
First, we will discuss the association between diabetes and cancer, including molecular interactions between IGF-1R and HER2 in BC. Then, the potential role of metformin and other T2DM drugs in the management of HER2-positive BC will be reviewed. Lastly, we conclude with a short summary on ...
Genetic amplification of HER2 drives tumorigenesis and cancer progression in a subset of patients with gastric cancer (GC), and treatment with trastuzumab, a humanized HER2-neutralizing antibody, improves the overall survival rate of HER2-positive patients. However, a considerable portion of the patient...